selected publications
- Chimeric antigen receptor T cells for autoimmune diseases, in particular immune thrombocytopenia. British journal of haematology. 2026 Information Resource GET IT
- Cell-surface targets for prostate cancer therapeutics. Urologic oncology. 2026 Information Resource GET IT
- Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics. Revista espanola de medicina nuclear e imagen molecular. 2025 Information Resource GET IT
-
Advances in PSMA-Targeted Radionuclide Therapeutics.
Current treatment options in oncology.
2025
Information Resource
GET IT
Times cited: 3 -
Antibody-drug conjugates in urothelial carcinoma: current status and future.
Current opinion in urology.
2025
Information Resource
GET IT
Times cited: 4 -
Quantification of collagen content and stromal cellularity within reactive stroma is predictive of prostate cancer biochemical recurrence and specific death.
Human pathology.
2023
Academic Article
GET IT
Times cited: 3 -
Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis.
Human pathology.
2022
Academic Article
GET IT
Times cited: 20 -
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
European urology.
2019
Information Resource
GET IT
Times cited: 42